Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trila...
2024-01-09 07:55:26 ET Summary G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple-negative breast cancer. The company aims to pursu...
- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for Patients Receiving Trilaciclib - - COSELA® (trilaciclib) Vial Volume Growth Accelerat...
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42 nd Annual J.P. Morgan Healthcare ...
2023-12-14 08:07:49 ET XBP Europe Holdings ( XBP ) +151% . Hanryu Holdings ( HRYU ) +33% . Codexis ( CDXS ) +13% sign exclusive licensing deal for Codex HiCap RNA polymerase. Esperion Therapeutics ( ESPR ) +11% labels o...
2023-12-11 12:51:49 ET Gainers: Jet.AI ( JTAI ) +70% . Boqii Holding Limited ( BQ ) +34% . Marker Therapeutics ( MRKR ) +34% . Morphosys AG ( MOR ) +25% . G1 Therapeutics ( GTHX ) +24% . Innoviz Technologies Ltd ( INVZ ) ...
2023-12-11 08:00:00 ET Summary G1 Therapeutics' lead drug trilaciclib experienced setbacks, but recent presentations on its potential benefits in breast cancer have sparked interest in the stock. Trilaciclib is designed to protect normal cells during chemotherapy and has been appr...
2023-12-06 14:48:10 ET Penny Stocks – How News Makes These Small Caps Soar or Plunge Penny stocks , securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks require...
- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved Long-Term Survival with Subsequent Anticancer Therapies - - Improved Long-Term Survival A...
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast ca...
News, Short Squeeze, Breakout and More Instantly...
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of...